KEAP1 and large cell neuroendocrine carcinoma: Based on these data patients with “SCLC like” LCNEC subtype with WT RB1, WT KEAP1, WT STK11 and loss of neuroendocrine markers, could benefit from CDK4/6 inhibitors.